What this study is
Evaluation of current and newly developed endoluminal therapies in the management of Upper and Lower GI conditions.
What's being tested
- Endoscopic Intervention
Intervention · PROCEDURE
After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
Study details
- Official title
- Outcome Analysis of Endoluminal Therapies for Gastrointestinal Conditions Compared to Current Treatment Paradigms
- Sponsor
- University of California, Davis
- Conditions
- Achalasia · Gastric Fistula · Weight Gain After Primary Weight Loss Surgery · Marginal Ulcer · Stenoses · Gastric Nec
- Enrolling
- 500 people
- Starts
- 2016-03
- Est. completion
- 2031-12
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 80 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Adult male and female patients 18-80 years of age
- Meet the criteria for surgery of benign and/or malignant gastrointestinal pathology(s)
- Gastrointestinal Reflux Disease
- Achalasia
- Barrett's Esophagus
- Post Bariatric Surgery conditions
- Other gastrointestinal and postsurgical disorders.
You can't join if
- Adults unable to consent
- Individuals that do not meet inclusion criteria or qualify for endoluminal treatment paradigms and internees.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUnivesity of California Davis Health System
Sacramento, California, United States
Study team
Sponsor
University of California, Davis
Study ID 676956
Principal investigator
Mohamed R Ali, MD
U.C. Davis Medical Center
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.